One of the immunotherapies that target immune checkpoints, represented by blockade of programmed cell death protein 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1), has been approved for clinical treatment of RCC patients [3]. The gene discussed is PDCD1; the disease is renal cell carcinoma.